Condition
Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs
Estimated Enrollment: 160
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 2016-0861|NCI-2017-00501
Study First Received: February 22, 2017
Last Updated: April 19, 2017
Estimated Primary Completion Date: March 2021
Primary Outcome Measures:
Overall Response Rate of Atezolizumab in Combination with Bevacizumab|Adverse Events of Atezolizumab in Combination with Bevacizumab
Sponsors and Collaborators:
M.D. Anderson Cancer Center|Genentech, Inc.
Website Link: https://ClinicalTrials.gov/show/NCT03074513
